2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients
2010
Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature
Caldwell C, Werdiger N, Jakab S, Schilsky M, Arvelakis A, Kulkarni S, Emre S. Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transplantation 2010, 16: 818-826. PMID: 20583082, DOI: 10.1002/lt.22077.Peer-Reviewed Original ResearchConceptsEarly liver transplantationHepatic myelopathyLiver transplantationSpastic paraparesisEnd-Stage Liver Disease (MELD) exception pointsEnd-Stage Liver Disease exceptionCases of LTException pointsCorticospinal tract functionFurther hepatic decompensationSetting of cirrhosisSignificant neurological improvementProgressive spastic paraparesisMELD exception pointsHepatic decompensationMELD scoreNeurological improvementFull ambulationNeurological benefitsPortosystemic shuntingHM patientsClinical stageUnited NetworkWheelchair dependencyEarly transplantation